Biofrontera
BFRIW
6 hedge funds and large institutions have $19.8K invested in Biofrontera in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 3 reducing their positions, and 1 closing their positions.
60% more capital invested
Capital invested by funds: $12.4K → $19.8K (+$7.41K)
10.33% more ownership
Funds ownership: 2.28% → 12.61% (+10%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$996 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$2.11K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$54 |
| 3 |
CS
Clear Street
New York
|
-$17 |
| 4 |
TSS
Two Sigma Securities
New York
|
-$8 |
BFRIW Hedge Fund Activity: Q2 2025 in Review
6 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Biofrontera (BFRIW) for Q2 2025, worth a combined $19.8K — up 60% from $12.4K a quarter earlier.
Fund positioning in BFRIW was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $996. The largest seller was Bard Associates, cutting an estimated $2.11K.
- 6 institutional investors held Biofrontera (BFRIW) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $19.8K of Biofrontera stock for Q2 2025, up 60% quarter-over-quarter.
- 1 fund opened new Biofrontera positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest Biofrontera buyer in Q2 2025 was Susquehanna International Group, an estimated $996 added.
- The largest Biofrontera seller in Q2 2025 was Bard Associates, an estimated $2.11K sold.
Based on aggregated 13F filings for Q2 2025.